Concepedia

Luckson Mathieu

LM

Statistics

Publications

7

Citations

606

H-Index

7

Active since

2013

Affiliations

United States Food and Drug Administration(Current)

Center for Drug Evaluation and Research

Johns Hopkins University

Johns Hopkins Medicine

Luckson Mathieu is an author at United States Food and Drug Administration specializing in oncology, medicine, and cancer survival analysis.

ORCID

Publications per year

2013–2023

7

Publications

7

FDA Approval Summary: Dabrafenib and Trametinib for the Treatment of Metastatic Non-Small Cell Lung Cancers Harboring <i>BRAF V600E</i> Mutations

Lauretta Odogwu, Luckson Mathieu, Gideon M. Blumenthal et al. · The Oncologist · 2018 · 217 citations · Full text

, , +13

Age and sex differences in the incidence of esophageal adenocarcinoma: results from the Surveillance, Epidemiology, and End Results (SEER) Registry (1973-2008)

Luckson Mathieu, Norma Kanarek, Hai-Lung Tsai et al. · Diseases of the Esophagus · 2013 · 116 citations · Full text

, , +17

Outcomes of anti–PD-(L)1 therapy with or without chemotherapy (chemo) for first-line (1L) treatment of advanced non–small cell lung cancer (NSCLC) with PD-L1 score ≥ 50%: FDA pooled analysis.

Oladimeji Akinboro, Jonathon Vallejo, Erica C. Nakajima et al. · Journal of Clinical Oncology · 2022 · 82 citations

, , +13

Survival After Community Diagnosis of Early-stage Non-small Cell Lung Cancer

Norma Kanarek, Craig M. Hooker, Luckson Mathieu et al. · The American Journal of Medicine · 2014 · 67 citations

, , +6

FDA Benefit-Risk Assessment of Osimertinib for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor T790M Mutation

Lauretta Odogwu, Luckson Mathieu, Kirsten B. Goldberg et al. · The Oncologist · 2017 · 63 citations · Full text

, , +13

1–5 of 7